TScan Therapeutics’ (TCRX) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $11.00 price objective on the stock.

Several other analysts have also recently issued reports on TCRX. Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective (down previously from $10.00) on shares of TScan Therapeutics in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Wednesday.

TScan Therapeutics Trading Down 5.6 %

Shares of TScan Therapeutics stock opened at $2.85 on Wednesday. The firm has a 50-day simple moving average of $4.82 and a two-hundred day simple moving average of $5.87. The company has a market cap of $152.10 million, a P/E ratio of -2.69 and a beta of 0.79. TScan Therapeutics has a fifty-two week low of $2.60 and a fifty-two week high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, equities analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Barbara Klencke purchased 5,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was acquired at an average price of $5.29 per share, with a total value of $26,450.00. Following the purchase, the director now directly owns 45,000 shares in the company, valued at approximately $238,050. This represents a 12.50 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.76% of the company’s stock.

Hedge Funds Weigh In On TScan Therapeutics

Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP acquired a new stake in TScan Therapeutics during the 2nd quarter worth approximately $70,000. The Manufacturers Life Insurance Company acquired a new stake in TScan Therapeutics during the 2nd quarter worth approximately $90,000. SG Americas Securities LLC acquired a new stake in TScan Therapeutics during the 3rd quarter worth approximately $78,000. XTX Topco Ltd acquired a new stake in TScan Therapeutics during the 3rd quarter worth approximately $112,000. Finally, Cornercap Investment Counsel Inc. acquired a new stake in TScan Therapeutics during the 2nd quarter worth approximately $134,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.